

IP MARKETPLACE

CONNECTING INNOVATION TO YOUR BUSINESS

TECH OFFER

AN ANTIGENIC RECOMBINANT HYPOTHETICAL LIPOPROTEIN FROM BURKHOLDERIA PSEUDOMALLEI AND A NOVEL METHOD THEREOF



▶ MORE INFORMATION

MEGA-TREND

- **Chemicals and Materials**

TECHNOLOGY READINESS LEVEL (TRL)

- **TRL 3**

PATENT/ GRANTED NUMBER

- **PI 2016704195**

▶ TECHNOLOGY OVERVIEW

The present invention discloses a design and production of a recombinant antigen based on a hypothetical lipoprotein (rHLP) (rBurP16-532) from Burkholderia pseudomallei and a novel method for synthesizing an antigenic recombinant hypothetical lipoprotein (rHLP) from Burkholderia pseudomallei. The method comprises series of steps: 1. construction of recombinant plasmid; 2. Expression and purification of recombinant lipoprotein; 3. analysis of purified recombinant lipoprotein; and 4. confirming the reactivity of the purified recombinant lipoprotein (rHLP).

The pTriEx_rBurP16-532 plasmid containing the gene sequence for residues 16-532 of the *B. pseudomallei* hypothetical lipoprotein (rBurP16-532) cloned into the pTriEx-3 Hygro expression vector, wherein the vector expresses the rHLP protein, consisting the HIG and FLAG tag fused to the N-terminus of the residues 16-532 of the *B. pseudomallei* hypothetical lipoprotein. The hypothetical lipoprotein (rHLP) (rBurP16-532) is reactive to the antibodies produced in the sera of melioidosis patients and is used for different medical and healthcare purposes mainly as vaccine or diagnostic agent against the disease of melioidosis.

CONTACT US!

Dr. Lee Ching Shya

UMCIE Business Officer

Email: leecs@um.edu.my

Phone: +603 – 7967 7351 / 7352